Radcliffe Vascular (@radcliffevascu) 's Twitter Profile
Radcliffe Vascular

@radcliffevascu

🖥 Webinar Makers 🎥 Interview Creators Publishers of a peer-reviewed journal 📚Supporting vascular physicians worldwide #clifighters #radialfirst #meded

ID: 954730278240636929

linkhttp://www.radcliffevascular.com/ calendar_today20-01-2018 15:00:11

1,1K Tweet

1,1K Takipçi

2,2K Takip Edilen

Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

💡Dr Michel Bosiers discusses the MOTIV trial investigating the safety and effectiveness of the MOTIV sirolimus-eluting bioresorbable vascular scaffold vs balloon #angioplasty for the treatment of infrapopliteal lesions. 📽️👉 ow.ly/fZJW50VQ71u

Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

💡Prof Andrew Holden discusses two new #IVL devices addressing calcified tibial disease, the Shockwave E8 catheter and the Shockwave Javelin catheter. 📽️👉 ow.ly/TuqG50VQ8py #BTK

Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

💡Dr Ari Kramer discusses an observational study using the FLEX FIRST AV registry, which aimed to assess the FLEX Vessel Prep system followed by plain balloon #angioplasty. 📽️👉 ow.ly/CQBH50VR18V

Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

💡Prof Andrew Holden discusses a study comparing the GORE VBX balloon-expandable covered stent to non-covered balloon-expandable stents in patients with complex #aortoiliac occlusive disease. 📽️👉 ow.ly/2lsg50VRe5O

Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

💡Dr Catherine Go discusses outcomes from the first retrospective trial evaluating the impact of GLP-1 medications for patients with moderate #PAD. 📽️👉 ow.ly/k9jl50WcX7h 📊GLP-1 medications significantly decreased the risk of amputations. #GLP1 #MedEd

Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

📚 Latest News : "BRIDGE-TNK: Tenecteplase Before Thrombectomy Improves Functional Outcomes in Stroke" 🔓Access it here 👉 ow.ly/VmJS106fX5t

📚 Latest News : "BRIDGE-TNK: Tenecteplase Before Thrombectomy Improves Functional Outcomes in Stroke"

 🔓Access it here 👉 ow.ly/VmJS106fX5t
Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

🎙️NEW #ESCCongress 2025 🔥 Hot Line Interview 🌟 Dr Gregory Piazza joins to discuss findings from the HI-PRO trial. 📽️ ow.ly/qmp950WOAGN HI-PRO shows #apixaban 2.5mg twice daily reduced the risk of symptomatic recurrent venous thromboembolism vs placebo at 12 months.

Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

🎙️NEW #ESCCongress 2025 💫 #LBCT Interview 🌟 Dr Oliver Schlager joins us to discuss the newly released 2025 #ESVM guidelines on interventional treatment of #venous #thromboembolism. 📽️Watch here👉 ow.ly/T3rp50WPb6I #ESCCongress2025 #ESC2025 #CardioEd

Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

🎙️NEW #ESCCongress 2025 🔥 Hot Line Interview 🌟 Dr Mårten Falkenberg & Prof Joakim Nordanstig discuss findings from the SWEDEPAD 1 & 2 studies. 📽️👉 ow.ly/FQii50WQfGA #Paclitaxel #CLTI #ESCCongress2025 #ESC2025

Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

📚 Latest News : "HI-PRO: Low-Dose Apixaban Reduces Recurrent VTE in Provoked Cases with Enduring Risk" 🔓Access it here 👉 ow.ly/L0hx106l9oI

📚 Latest News : "HI-PRO: Low-Dose Apixaban Reduces Recurrent VTE in Provoked Cases with Enduring Risk"

 🔓Access it here 👉 ow.ly/L0hx106l9oI
Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

📚 Latest News : "Intensive LDL-C Lowering with Evolocumab Does Not Reduce Early Vein Graft Failure After CABG" 📚 Intensive LDL-C lowering with evolocumab post-CABG fails to prevent early vein graft failure in the NEWTON-CABG trial. 👉 ow.ly/12SZ106lg1J

📚 Latest News : "Intensive LDL-C Lowering with Evolocumab Does Not Reduce Early Vein Graft Failure After CABG"

📚 Intensive LDL-C lowering with evolocumab post-CABG fails to prevent early vein graft failure in the NEWTON-CABG trial.

 👉 ow.ly/12SZ106lg1J
Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

🎙️NEW #CIRSE2025 #LBCT Interview 🌟 Prof Marianne Brodmann joins to discuss findings from the BIONETIC-I study. 📽️👉 ow.ly/RKTF50WYiJN 📊24-month results show the Biotronik Dynetic-35 cobalt chromium balloon-expandable stent was safe and effective in iliac arteries.

Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

🎙️NEW #CIRSE2025 #LBCT Interview 🌟 Dr Fernando Gómez Muñoz joins to discuss findings from stage I of the first-in-human pivotal study investigating the safety and efficacy of the amber peripheral liquid embolic system in peripheral embolisation. 📽️👉 ow.ly/puP950WYiSj

Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

📚 Latest News : "Paclitaxel-Coated Devices Do Not Reduce Amputation Risk in Chronic Limb-Threatening Ischaemia" 🔓Access it here 👉 ow.ly/9lVw106lJ8c

📚 Latest News : "Paclitaxel-Coated Devices Do Not Reduce Amputation Risk in Chronic Limb-Threatening Ischaemia"

 🔓Access it here 👉 ow.ly/9lVw106lJ8c
Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

🚨 We have exciting updates for Vascular Intervention Online - Venous Edition! Swipe across to meet the expert faculty shaping (VIO) learning and explore the agenda to plan your day. Register Here: ow.ly/sqtc50X3Ecr

🚨 We have exciting updates for Vascular Intervention Online - Venous Edition!

Swipe across to meet the expert faculty shaping (VIO) learning and explore the agenda to plan your day. 

Register Here: ow.ly/sqtc50X3Ecr
Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

🚨 Vascular Interventions Online (VIO) 2025 – #Venous Edition goes live today! Join us from 16:00 BST | 17:00 CEST for an unmissable educational experience Register now 👉 ow.ly/5fWI50X8lGN 💻 Free to attend and designed for vascular specialists worldwide #VIO2025 #DVT

🚨 Vascular Interventions Online (VIO) 2025 – #Venous Edition goes live today!

Join us from 16:00 BST | 17:00 CEST for an unmissable educational experience

Register now 👉 ow.ly/5fWI50X8lGN

💻 Free to attend and designed for vascular specialists worldwide

#VIO2025 #DVT
Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

⏰ We’re going live in just 1 hour! #VIO2025 – #Venous Edition begins at 16:00 BST | 17:00 CEST! 🎓Join thousands of vascular professionals for expert-led education on cutting-edge venous interventions. Tune in here 👉 ow.ly/QoHA50X8ny0

⏰ We’re going live in just 1 hour!

#VIO2025 – #Venous Edition begins at 16:00 BST | 17:00 CEST! 

🎓Join thousands of vascular professionals for expert-led education on cutting-edge venous interventions.

Tune in here 👉 ow.ly/QoHA50X8ny0
Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

🔴Vascular Interventions Online (#VIO) 2025 – Venous Edition is LIVE! Join us free now 👉 ow.ly/QEQr50X8A0r 💬 Don’t miss the chance to interact with global experts and learn the latest in venous intervention techniques. #VIO2025 #VenousCare #Thrombectomy #DVT

🔴Vascular Interventions Online (#VIO) 2025 – Venous Edition is LIVE!

Join us free now 👉 ow.ly/QEQr50X8A0r

💬 Don’t miss the chance to interact with global experts and learn the latest in venous intervention techniques.

#VIO2025 #VenousCare #Thrombectomy #DVT
Radcliffe Vascular (@radcliffevascu) 's Twitter Profile Photo

📚 Latest News : "COVID-19 Linked to Vascular Ageing, Especially in Women" 📚 A new study suggests COVID-19 infection may accelerate vascular ageing, with a more pronounced effect in women, correlating with disease severity and long COVID symptoms. 👉 ow.ly/s8NB106oNIC

📚 Latest News : "COVID-19 Linked to Vascular Ageing, Especially in Women"

📚 A new study suggests COVID-19 infection may accelerate vascular ageing, with a more pronounced effect in women, correlating with disease severity and long COVID symptoms.

 👉 ow.ly/s8NB106oNIC